Biotech Penny Stocks To Watch Check Cap Ltd

techmanga June 27, 2021 0 Comments



Top 10 Biotech Penny Stocks to Watch


Following are the top 10 biotech penny stocks to watch today, these are thebiotech penny stocks that made big moves. * Imac Holdings Inc (NASDAQ:IMAC) * Therapeuticsmd Inc (NASDAQ:TXMD) * Nabriva Therape Ads (NASDAQ:NBRV) * Abeona Therapeutics (NASDAQ:ABEO) * Iterum Therapeutics Plc (NASDAQ:ITRM) * Noven Pharmaceuticals, Inc (NASDAQ:NOVN) * Cellectar Biosc (NASDAQ:CLRB) * Teligent Inc (NASDAQ:TLGT) * Agile Therap (NASDAQ:AGRX) * Acelrx Pharmaceutica (NASDAQ:ACRX)

Top 10 Biotech Penny Stocks to Watch


Following are the top 10 biotech penny stocks to watch today, these are thebiotech penny stocks that made big moves. * Imac Holdings Inc (NASDAQ:IMAC) * Therapeuticsmd Inc (NASDAQ:TXMD) * Nabriva Therape Ads (NASDAQ:NBRV) * Abeona Therapeutics (NASDAQ:ABEO) * Iterum Therapeutics Plc (NASDAQ:ITRM) * Noven Pharmaceuticals, Inc (NASDAQ:NOVN) * Cellectar Biosc (NASDAQ:CLRB) * Teligent Inc (NASDAQ:TLGT) * Agile Therap (NASDAQ:AGRX) * Acelrx Pharmaceutica (NASDAQ:ACRX)

Biotech Penny Stocks To Watch


These biotech penny stocks are on watch, thanks to upcoming events thisquarter. Some of these are more near-term than others. Needless to say, itcould present a risky scenario. Again, the outcome of these events couldtrigger big moves (in either direction) for these penny stocks. With that inmind, will any of these be on your watch list heading into the second half ofQ1?Penny Stocks To Watch As Biotech Takes Center Stage In 2020

Biotech Penny Stocks To Watch: Revive Therapeutics Ltd.


Shares of Revive Therapeutics Ltd. (RVVTF Stock Report) (RVV) has been on aslow rise over the last few months. if you look at the chart, you’ll obviouslysee big spikes, including the recent jump to highs of $0.50. But then if youlook at some technical levels, you’ll notice that RVVTF stock has followedalong with its 50-day moving average since March. That has seen the biotechpenny stock climb from around $0.04 at the time to recent trading levels of$0.19. A consistent move of 375% heading into August and after its last bigupdate could be something to note.At the end of June, Revive announced the submission of an Investigational NewDrug application to the U.S. FDA. This was for a Phase 3 confirmatory studyfor Bucillamine. The trial is to see Bucillamine as a potential treatment inCOVID-19. The company has also previously met with Health Canada in a Pre-Clinical Trial Application meeting. Revive also said that it intends to followup with the submission of the complete CTA package for Health Canada aroundits Phase 3 study as part of the same multinational clinical strategy.As far as the first Phase 3 study is concerned, once the U.S. FDA allows theIND to go into effect, Revive said it will initiate a randomized, double-blind, placebo-controlled study of Bucillamine in patients with mild-moderateCOVID-19 in Q3-2020. With much more attention on coronavirus vaccine stocks,it’s not surprising to see this momentum in July. Is August setting up toexperience something similar?

Biotech Penny Stocks To Watch: CHF Solutions


Another one of the penny stocks we’ve followed closely lately is CHF Solutions(CHFS Stock Report). This is more on the bio-technology/device side of theindustry and the company has been making progress with its ultrafiltrationtherapy. CHF’s Aquadex SmartFlow™ system is used for managing fluid overloadin patients with renal and other diseases.CHF has fallen into the list of coronavirus penny stocks to watch especiallyconsidering the uses of its ultrafiltration therapy. Fluid overload or“hypervolemia” is an issue among critically ill children and adults, includingpatients hospitalized with COVID-19, heart failure, and kidney disease. Thisweek the company announced another key update. CHF reported that it signed adistribution agreement with SysteMedic Ltd covering Israel and Palestine. Thisis the company’s second distribution partnership in the Middle East and bringsits therapy availability to 16 countries outside the U.S.On top of that, a mid-morning tweet triggered some additional, bullishsentiment on Thursday. CHF said that its Aquadex “usage to stabalize COVID-19patients has grown in Florida due to the second wave of the virus. 3 newhospitals in Central Florida just added ultrafiltration as an alternativetherapy for fluid management.”[Read More] What Are The Best Penny Stocks To Buy Right Now? 1 Up 122% In JulyCHFS stock has rallied strong this year. Since the end of February, thecompany has been on watch lists. At the time, the penny stock traded around$0.40. As of this week, CHFS stock reached a high of $0.8912 so far. DoesAugust have more in store?

Biotech Penny Stocks to Watch: Seelos Therapeutics Inc.


Seelos Therapeutics Inc. (SEEL Stock Report) has been on the watch list sincemid-May and is somewhat of a “slow mover”. It’s also one of the few listedpenny stocks to have a foot in the emerging psychedelics industry. Revive,mentioned earlier, as well as other OTC-listed penny stocks are more popularfor the emergence and popularity of psychedelics.However, in Seelos’ case, anyone looking for listed mushroom stocks could havecome across this in their travels. The company’s pipeline products includeSLS-002, for instance. This is intranasal racemic ketamine for patients withsuicidality in post-traumatic stress disorder and depressive disorder. Besidesthat, the company has a growing pipeline of rare disease drug candidates aswell.In May we saw two announcements spark initial interest. First, the companyannounced that it has been granted Rare Pediatric Disease Designation forSLS-005 in Sanfilippo syndrome from the U.S. FDA. Seelos then announced theappointment of F. Hoffman-La Roche alum, Judith Dunn to its Board. In June Thecompany received feedback from the FDA supporting the design of a 16-day studyfor Acute Suicidal Ideation and Behavior in patients with Major DepressiveDisorder. Seelos plans on starting that this fall.This month, the company received a positive opinion on European Orphan DrugDesignation for SLS-005 from the European Medicines Agency Committee forOrphan Medicinal Products. SLS-005 has also been granted Fast Trackdesignation from the FDA for Oculopharyngeal Muscular Dystrophy.Click Here For Full Disclaimer* * ** * *Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146| news@pennystocks.comTop Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021

4 Biotech Penny Stocks to Watch Right Now


Now, when looking for a biotech penny stock to buy, there are a few things toconsider. First and foremost is, what does its pipeline look like? Thisincludes knowing how many drugs it has in development, and where those drugsare in the various stages of approval.[Read More]3 Penny Stocks on Robinhood for Your April WatchlistNext, how is its financial situation? Has it engaged in any fundraising roundsor does it have a large balance of cash on hand? This information can help toidentify potential long-term business opportunities and whether or not it canfund ongoing/future trials and research.These are all equally important aspects to consider for all prospectivebiotech investors. So with this in mind, are these the top penny stocks to buyfor May 2021? 1. Iterum Therapeutics Plc. (NASDAQ: ITRM) 2. Onconova Therapeutics Inc. (NASDAQ: ONTX) 3. Asensus Surgical Inc. (NYSE: ASXC) 4. Zomedica Corp. (NYSE: ZOM)

4 Biotech Penny Stocks to Watch Right Now


Now, when looking for a biotech penny stock to buy, there are a few things toconsider. First and foremost is, what does its pipeline look like? Thisincludes knowing how many drugs it has in development, and where those drugsare in the various stages of approval.[Read More]3 Penny Stocks on Robinhood for Your April WatchlistNext, how is its financial situation? Has it engaged in any fundraising roundsor does it have a large balance of cash on hand? This information can help toidentify potential long-term business opportunities and whether or not it canfund ongoing/future trials and research.These are all equally important aspects to consider for all prospectivebiotech investors. So with this in mind, are these the top penny stocks to buyfor May 2021? 1. Iterum Therapeutics Plc. (NASDAQ: ITRM) 2. Onconova Therapeutics Inc. (NASDAQ: ONTX) 3. Asensus Surgical Inc. (NYSE: ASXC) 4. Zomedica Corp. (NYSE: ZOM)

Top Biotech Penny Stocks To Watch


Biotech penny stocks have evolved since 2020 began. What has mainly driventhese stocks is the coronavirus pandemic. The COVID-19 outbreak has causedmany hurdles that people did not expect this year. This has caused biotechcompanies to scramble in search of a vaccine that will work. The goal is toend the pandemic and go back to our everyday lives.We are actively living in a world where COVID-19 is still spreading. Thesearch for a feasible vaccine or treatment is on but is still yet to have awidespread solution. This virus has caused many biotech companies who wereotherwise unknown to show up in the news. There is still a lot of uncertaintyabout this virus, which is why more than 200 companies are attemptingdevelopments.Read MoreThe market for biotech stocks is always changing, though. If one company makesmore advances for the same type of treatment, it could rise while the otherdeclines. When biotech companies receive government approval or launchwidespread trials, it can cause their stock price to move as well. It’s commonin this sector, especially with COVID-19 related companies. Now, let’s look at5 biotech penny stocks that are trending in the market.

Biotech Penny Stocks To Watch: Revive Therapeutics


Revive Therapeutics (RVVTF Stock Report) is a biotech company that createstherapeutics for medical needs and rare disorders. Currently, Revive has beenworking on a potential COVID-19 treatment called Bucillamine. On August 5th,the company gave an update on its previously announced FDA approval to proceedwith its Phase 3 in July.The CEO of Revive, Michael Frank, said, “With the FDA approval of the Phase 3clinical study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, our team and partners are working diligently to align ourresources and expertise that will fast-track the Phase 3 study.” On August31st, Revive announced that it won Institutional Review Board approval for itsPhase 3 trial to evaluate Bucillamine in patients with the virus.Mr. Frank additionally said, “With the IRB approval of the Phase 3 studyprotocol for COVID-19, we can recruit U.S. clinical sites efficiently,allowing us to move forward with providing Bucillamine to patients under ourInvestigational New Drug (IND) application that was approved by the FDA lastmonth.”Phase 3 will track 1000 patients that will be randomized to receive 100mg ofBucillamine three times a day for 14 days. As far as timing is concerned, thismonth could be an important one for Revive. The company said in its August26th PR that it expects to have patients enrolled in September 2020. Aninterim analysis will be performed by an Independent Data and SafetyMonitoring Board after 210 patients have been treated and followed up for 28days after randomization.

Biotech Penny Stocks To Watch: InspireMD Inc.


Why did InspireMD Inc. (NSPR Stock Report) just see an uptick? Let’s firsttalk about who InspireMD is. This company focuses on creating medical devices,developing, and commercializing different technologies. These developmentstreat things like coronary and vascular diseases. InspireMD just announcedthat its study of CGuard Carotid Stent System, CARENET-III, was approved toproceed by the US FDA. This goal is to help prevent people from gettingstrokes.The CEO of InspireMD, Marvin Slosman, said, “This is a key milestone in thehistory of our company as it helps pave the way for us to initiate a clinicaltrial of CGuard EPS for addressing Carotid Artery Disease and preventingstroke in the United States market. This will be the first U.S.-based study ofCGuard which is a cornerstone of our global expansion plans. A pivotal trialof this kind requires significant preparation and allocation of resources, andwe have already begun to move pieces into place in order to plan theinitiation of our CARENET-III study. The FDA approval of the IDE represents animportant step in enabling us to conduct a pivotal clinical trial todemonstrate the potential for CGuard EPS against carotid artery disease.”[Read More] Top Penny Stocks To Watch Today Following Key UpdatesTime will tell how these advancements help NSPR stock price. On September 8th,NSPR stock reached an intra-day high of $0.495. However, considering theaggressive pullback from those highs, will this penny stock remain a focus fortraders in September?

Biotech Penny Stocks To Watch: Evofem Biosciences Inc.


Another one of the biotech penny stocks to watch is Evofem Biosciences Inc.(EVFM Stock Report). Evofem is a biotech company that develops andcommercializes products targeted at women’s sexual and reproductive help. Thecompany reported its second-quarter financial results for 2020 on August 4th.Operating expenses were $22.4 million compared to $11.9 million, year overyear. Its research and development costs were $2.6 million compared to $5.2million, year over year.The CEO of Evofem, Saundra Pelletier, said, “The second quarter of 2020 wasmarked by success across all areas of our business. With the FDA approval ofPhexxi in hand, more than $130 million in gross proceeds from our twofinancing transactions on the books, and clear guidance from the FDA regardingthe clinical path forward for EVO100, we are operating from a position ofstrength with a clear vision for the future.”Furthermore, on September 8th, Evofem announced the official U.S. commerciallaunch of its contraceptive, Phexxi. The biopharmaceutical firm also said thatit is launching the Phexxi Concierge Experience, a comprehensive woman-centrictelemedicine support system, to help ensure accessibility to the contraceptiveproduct. Considering that this event has long been expected, it will beinteresting to see what comes next for EVFM this year.

Biotech Penny Stocks To Watch: Check-Cap Ltd.


The final biotech penny stock to watch is Check-Cap Ltd. (CHEK Stock Report).Check-Cap is a medical diagnostics company that develops a capsule-basedsystem for x-rays. The company also introduced its C-Scan product foridentifying certain GI cancers. On August 5th, Check-Cap reported its second-quarter financial results for 2020.[Learn More] Penny Stocks & Due Diligence: Understanding Important SEC FilingsThe CEO of Check-Cap, Alex Ovadia, had this to say, “I am happy with theprogress we made during the first six months of 2020 and delighted to observeour team’s commitment despite the ongoing global COVID-19 crisis.”While the company’s progress was slowed early on things have resumed nearnormal operations. The company expressed that this included its ongoingcollection of clinical data in Israel.In particular, that collection has been going on during the third quarter.Could this be something to note heading into the end of September for CHEKstock?The company was able to narrow its net loss from $3.4 million in Q2 2019to $2.9 million this year. Furthermore, management revealed that it plans tosubmit an Investigational Device Exemption to the FDA for C-Scan by the end ofthis year.Subsequently, it aims to begin a U.S. pivotal study of the device in 2021.While August wasn’t a stellar month for CHEK, this month has seen a bit moreexcitement. From September 4th to the 8th, CHEK stock is up 22% with volumetrending well-above average. Can this trend continue through the rest of thethird quarter?

Leave a Reply

Your email address will not be published. Required fields are marked *